Do Analysts Expect Solid Biosciences Inc (SLDB) Stock to Rise After It Has Risen 42.95% in a Month?

Analysts who follow Solid Biosciences Inc (SLDB) on average expect it to lose -37.31% over the next twelve months. Those same analysts give the stock an average rating of Buy. That average rating earns the stock an Analyst Ranking of 37, which means it ranks higher than 37 of stocks, based on data compiled by InvestorsObserver.

Wall Street analysts are rating SLDB a Buy today. Find out what this means to you and get the rest of the rankings on SLDB!

See Full SLDB Report

Why are Analyst Ratings Important?

You can learn a lot about a company from looking at it’s financial statements and comparing them to other companies. Analysts who cover an industry in depth can add even more to your research though. They typically follow a particular sector or industry very closely. They also pay attention to and ask questions on earnings conference calls and other events where they might learn information that does show up in the numbers. InvestorsObserver takes the average rating from these analysts, and then percentile ranks those averages. This lets you compare stocks in a much more granular way than just seeing the typical five-tiered rating system used on most of Wall Street.

What's Happening With Solid Biosciences Inc Stock Today?

Solid Biosciences Inc (SLDB) stock has risen 6.51% while the S&P 500 is lower by -0.55% as of 10:18 AM on Friday, Mar 15. SLDB has risen $0.80 from the previous closing price of $12.28 on volume of 48,890 shares. Over the past year the S&P 500 is higher by 29.34% while SLDB has risen 183.12%. SLDB lost -$5.15 per share the over the last 12 months. Click Here to get the full Stock Report for Solid Biosciences Inc stock.